Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.11%
1,109.43
+1.20
+0.11%
—1,108.231,109.651,115.881,105.94——
SIXC
Communications
SIXC
Communications
SIXC
+0.77%
610.27
+4.64
+0.77%
—605.63605.63610.35602.96——
SIXE
Energy
SIXE
Energy
SIXE
-0.12%
1,208.45
-1.50
-0.12%
—1,209.951,210.981,211.681,197.20——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.40%
1,751.21
-7.02
-0.40%
—1,758.231,759.031,760.641,739.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.96%
628.85
-6.09
-0.96%
—634.94632.49632.49627.63——
SIXR
Staples
SIXR
Staples
SIXR
-0.14%
851.21
-1.16
-0.14%
—852.37850.81859.97849.13——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.75%
217.20
-1.65
-0.75%
—218.85218.85218.85215.61——
SIXT
Technology
SIXT
Technology
SIXT
+1.07%
3,566.28
+37.79
+1.07%
—3,528.493,565.203,568.733,509.18——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.08%
904.95
-9.87
-1.08%
—914.82910.36910.36897.78——
SIXV
Health care
SIXV
Health care
SIXV
+0.56%
1,480.55
+8.28
+0.56%
—1,472.271,470.891,481.751,466.47——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.49%
2,402.32
+11.71
+0.49%
—2,390.612,387.312,409.702,373.97——
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$14.60
+1.14%
(+0.16) 1D
May 13, 1:53:35 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMLX...
Open
$14.37
High
$14.74
Low
$14.24
Mkt. cap
1.62B
Avg. vol.
1.19M
Volume
487.18K
52-wk high
$18.60
52-wk low
$4.20
EPS
-$1.51
Beta
-0.11
Shares outstanding
111.19M
No. of employees
136
News stories
From sources across the web
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorPharmaceutical industry
Websiteamylyx.com
Last report
May 7, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
-$0.37 / -$0.35
-4.98%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
27.22M
19.86M
21.21M
27.61M
Cost of revenue
27.22M
19.86M
21.21M
27.61M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.64M
16.17M
15.39M
16.17M
Operating expense
15.64M
16.17M
15.39M
16.17M
Total operating expenses
42.86M
36.03M
36.60M
43.78M
Operating income
-42.86M
-36.03M
-36.60M
-43.78M
Other non operating income
-
-
-6.23M
-
EBT including unusual items
-41.44M
-34.39M
-32.95M
-41.28M
EBT excluding unusual items
-41.44M
-34.39M
-38.48M
-41.28M
Income tax expense
-
-
46.00K
-
Effective tax rate
-
-
-0.14%
-
Other operating expenses
-
-
-
-
Net income
-41.44M
-34.39M
-33.00M
-41.28M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.37
-0.30
-0.37
Interest and investment income
1.96M
1.82M
3.29M
2.57M
Interest expense
-
-
-
-
Net interest expenses
1.96M
1.82M
3.29M
2.57M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.72M
-35.91M
-36.50M
-43.68M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer